PCVX Vaxcyte, Inc.

8-K Current Report

Filed: February 24, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Vaxcyte, Inc. (PCVX) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• New ATM offering established Feb 24, 2026 — up to $500M in common stock via Leerink Partners, replacing prior Jefferies facility
• Placement agent fee up to 3.00% of gross proceeds — dilution cost to existing shareholders on any shares sold

+3 more insights

Other Vaxcyte, Inc. 8-K Filings

8-K Feb 24, 2026

Get deeper insights on Vaxcyte, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.